文献速递乳腺MR

新辅助化疗前MRI特征与治疗后MRI诊断准确性相关

Pretreatment MRI features associated with diagnostic accuracy of post-treatment MRI after neoadjuvant chemotherapy.
PubMed 文献 · Clin Radiol · 2018-03-19

研究纳入2005年1月至2016年12月221例连续接受新辅助化疗的浸润性乳腺癌患者,评估化疗前MRI特征与化疗后MRI预测病理完全缓解诊断准确性的关联。化疗后MRI诊断准确率为84.2%(186/221),假阳性21例、假阴性14例。化疗前瘤周水肿(OR 3)和HER2阳性(OR 3.4)与假阳性MRI结果显著相关;致密纤维腺体组织(OR 10.8)、环形强化(OR 7.5)和ER阳性(OR 6.3)与假阴性MRI结果显著相关。

要点

  • 化疗前存在瘤周水肿或HER2阳性的乳腺癌患者,化疗后MRI更易出现假阳性。
  • 化疗前致密纤维腺体组织、环形强化或ER阳性者,化疗后MRI更易出现假阴性。
  • 化疗后MRI预测病理完全缓解的总体诊断准确率为84.2%(186/221)。

核心结论

  • 化疗前MRI特征和肿瘤分子亚型可能与乳腺癌新辅助化疗后MRI的诊断准确性相关。

研究设计与样本

  • 回顾性纳入2005年1月至2016年12月221例连续接受新辅助化疗、化疗前后行乳腺MRI并手术的浸润性乳腺癌患者(平均年龄50岁,范围20-81岁),以术后病理为参考标准。

关键影像表现/征象

  • 化疗前瘤周水肿与化疗后MRI假阳性结果显著相关(OR 3;95%CI 1.1-8.0;p=0.03)。
  • 化疗前环形强化与化疗后MRI假阴性结果显著相关(OR 7.5;95%CI 1.2-38.3;p=0.02)。
  • 化疗前致密纤维腺体组织与化疗后MRI假阴性结果显著相关(OR 10.8;95%CI 1.1-105.2;p=0.04)。

诊断标准与关键数值

  • 影像学完全缓解定义为新辅助化疗后MRI上早期和晚期强化均缺失。
  • 化疗后MRI预测病理完全缓解的诊断准确率为84.2%(186/221),假阳性21例,假阴性14例。
  • 221例中60例(27.1%)在新辅助化疗后达到病理完全缓解。
  • HER2阳性与化疗后MRI假阳性结果显著相关(OR 3.4;95%CI 1.2-9.9;p=0.02)。
  • ER阳性与化疗后MRI假阴性结果显著相关(OR 6.3;95%CI 1.2-32.5;p=0.03)。

临床应用与阅片要点

  • 阅片时结合化疗前MRI特征(瘤周水肿、环形强化、纤维腺体组织密度)及HER2、ER状态,警惕化疗后MRI的假阳性或假阴性可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To investigate whether pretreatment magnetic resonance imaging (MRI) features are associated with diagnostic accuracy of post-treatment MRI for predicting pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with breast cancer.

MATERIALS AND METHODS: From January 2005 and December 2016, 221 consecutive patients (mean age, 50 years; range, 20-81 years) who had undergone NAC, breast MRI before and after NAC, and surgery for invasive breast cancer were enrolled. Pretreatment and post-treatment MRI images were reviewed. Radiological complete response (rCR) was defined as the absence of both early and late enhancement on MRI after NAC. The association of pretreatment MRI features and post-treatment MRI diagnostic accuracy was assessed by using logistic regression analysis.

RESULTS: Among 221 patients, 60 (27.1%) underwent pCR after NAC. The diagnostic accuracy of post-treatment MRI was 84.2% (186/221). False-positive diagnosis occurred in 21 cases and false-negative diagnosis occurred in 14 cases. Of pretreatment features, the presence of peritumoural oedema (odds ratio, 3; 95% confidence interval [CI]: 1.1, 8.0; p=0.03) and HER2 (human epidermal growth factor receptor 2)-positive status (odds ratio, 3.4; 95% CI: 1.2, 9.9; p=0.02) were significantly associated with false-positive MRI results. Dense fibroglandular tissue (odds ratio, 10.8; 95% CI: 1.1, 105.2; p=0.04), presence of rim enhancement (odds ratio, 7.5; 95% CI: 1.2, 38.3; p=0.02) and oestrogen receptor (ER)-positive status (odds ratio, 6.3; 95% CI: 1.2, 32.5; p=0.03) were significantly associated with false-negative MRI results.

CONCLUSION: Pretreatment MRI features and cancer subtypes may be associated with diagnostic accuracy of post-treatment MRI after NAC in patients with breast cancer.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Eun NL, Gweon HM, Son EJ, et al. Pretreatment MRI features associated with diagnostic accuracy of post-treatment MRI after neoadjuvant chemotherapy. Clin Radiol. 2018. PMID: 29567270. doi:10.1016/j.crad.2018.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。